Research1 week ago 5 min read
SS-31 (elamipretide) shows benefit in heart failure subgroup
A subgroup analysis of a phase 3 trial finds improvement in cardiomyopathy patients.
by Editorial team
The trial
A pre-specified subgroup of patients with Barth syndrome cardiomyopathy showed improved exercise capacity on elamipretide versus placebo.
The broader trial population did not meet its primary endpoint.
Why subgroups matter
Mitochondrial-targeted therapies may benefit patients with specific genetic or metabolic profiles more than general populations.
Regulators are increasingly open to disease-specific approvals based on subgroup data.
Outlook
The sponsor plans to file for approval in the Barth syndrome indication.
Broader uses remain investigational.